Genprex
GNPX
17 hedge funds and large institutions have $5.39M invested in Genprex in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
180% more call options, than puts
Call options by funds: $98K | Put options by funds: $35K
0% more ownership
Funds ownership: 0% → 0% (+0%)
6% less funds holding
Funds holding: 18 → 17 (-1)
7% less capital invested
Capital invested by funds: $5.8M → $5.39M (-$406K)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.48M |
| 2 |
Rockefeller Capital Management
New York
|
+$169K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$113K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$56.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$56.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$226K |
| 2 |
CC
Cypress Capital
Franklin,
Tennessee
|
-$145K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$56.4K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$56.4K |
| 5 |
VCP
Verus Capital Partners
Scottsdale,
Arizona
|
-$56.4K |
GNPX Hedge Fund Activity: Q1 2023 in Review
17 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q1 2023, worth a combined $5.39M — down 7% from $5.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GNPX and 5 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.48M. The largest seller was UBS Group, exiting entirely with an estimated $226K sold.
- 17 institutional investors held Genprex (GNPX) as of Q1 2023, down from 18 in Q4 2022.
- Funds reported $5.39M of Genprex stock for Q1 2023, down 7% quarter-over-quarter.
- 5 funds opened new Genprex positions in Q1 2023 and 6 closed out, a net change of -1 holder.
- The largest Genprex buyer in Q1 2023 was Armistice Capital, an estimated $2.48M added.
- The largest Genprex seller in Q1 2023 was UBS Group, an estimated $226K sold.
Based on aggregated 13F filings for Q1 2023.